Literature DB >> 16951216

Vascular endothelial growth factor signaling pathways: therapeutic perspective.

Marcin Kowanetz1, Napoleone Ferrara.   

Abstract

The establishment of a vascular supply is one of the earliest and most important events occurring during embryonic development. Growth and maturation of a functional vascular network are complex and still incompletely understood processes involving orchestrated activation of vascular progenitors in the early stages of embryonic development followed by vasculogenesis and angiogenesis. These processes require a tightly regulated activation of several growth factors and their receptors. The role of vascular endothelial growth factors (VEGF) and their receptors has been studied extensively due to their prominent role during blood vessel formation. Mice deficient in various VEGF ligands or receptors show serious defects in vascular formation and maturation. Moreover, members of the VEGF family are involved in other significant biological processes, including lymphangiogenesis, vascular permeability, and hematopoiesis. Importantly, VEGF is released by tumor cells and induces tumor neovascularization. It is now well established that the VEGF axis represents an important target for antitumor therapy. Aberrant VEGF signaling is also a feature of several other pathologic conditions, such as age-related macular degeneration and rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16951216     DOI: 10.1158/1078-0432.CCR-06-1520

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  187 in total

1.  Protein tyrosine phosphatase 1B impairs diabetic wound healing through vascular endothelial growth factor receptor 2 dephosphorylation.

Authors:  Jing Zhang; Limin Li; Jing Li; Yuan Liu; Chen-Yu Zhang; Yujing Zhang; Ke Zen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-11-13       Impact factor: 8.311

2.  Extending foldamer design beyond α-helix mimicry: α/β-peptide inhibitors of vascular endothelial growth factor signaling.

Authors:  Holly S Haase; Kimberly J Peterson-Kaufman; Sheeny K Lan Levengood; James W Checco; William L Murphy; Samuel H Gellman
Journal:  J Am Chem Soc       Date:  2012-05-01       Impact factor: 15.419

Review 3.  Roles for growth factors in cancer progression.

Authors:  Esther Witsch; Michael Sela; Yosef Yarden
Journal:  Physiology (Bethesda)       Date:  2010-04

4.  Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis.

Authors:  Ling Peng; Ping Zhan; Yun Zhou; Weijia Fang; Peng Zhao; Yulong Zheng; Nong Xu
Journal:  Mol Biol Rep       Date:  2012-06-23       Impact factor: 2.316

5.  Two-photon fluorescence vascular bioimaging with new bioconjugate probes selective toward the vascular endothelial growth factor receptor 2.

Authors:  Carolina D Andrade; Ciceron O Yanez; Hyo-Yang Ahn; Takeo Urakami; Mykhailo V Bondar; Masanobu Komatsu; Kevin D Belfield
Journal:  Bioconjug Chem       Date:  2011-10-04       Impact factor: 4.774

Review 6.  Bone Morphogenetic Protein functions as a context-dependent angiogenic cue in vertebrates.

Authors:  David M Wiley; Suk-Won Jin
Journal:  Semin Cell Dev Biol       Date:  2011-10-12       Impact factor: 7.727

7.  CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.

Authors:  Kavya Rakhra; Pavan Bachireddy; Tahera Zabuawala; Robert Zeiser; Liwen Xu; Andrew Kopelman; Alice C Fan; Qiwei Yang; Lior Braunstein; Erika Crosby; Sandra Ryeom; Dean W Felsher
Journal:  Cancer Cell       Date:  2010-10-28       Impact factor: 31.743

8.  4-isothiocyanate-2, 2, 6, 6-tetramethyl piperidinooxyl inhibits angiogenesis by suppressing VEGFR2 and Tie2 phosphorylation.

Authors:  Yuanyuan Liu; Jing Gao; Shuangsheng Huang; Lamei Hu; Zhiqiang Wang; Zheyuan Wang; Xiao Chen; Xiaoyu Zhang; Wenguang Li
Journal:  Oncol Lett       Date:  2016-08-03       Impact factor: 2.967

9.  VEGF-mediated fusion in the generation of uniluminal vascular spheroids.

Authors:  Carmine Gentile; Paul A Fleming; Vladimir Mironov; Kelley M Argraves; W Scott Argraves; Christopher J Drake
Journal:  Dev Dyn       Date:  2008-10       Impact factor: 3.780

10.  Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity.

Authors:  Zhiliang Jia; Yong Gao; Liwei Wang; Qiang Li; Jun Zhang; Xiangdong Le; Daoyan Wei; James C Yao; David Z Chang; Suyun Huang; Keping Xie
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.